Betmiga is an easy to use and effective treatment for overactive bladder syndrome. The prolonged release tablets deliver the active ingredient over an extended period of time, so that you can benefit from its effect for the entire day.
Tell our team of clinicians about your health and we will find the best treatment option for you.
Betmiga is an effective medication for overactive bladder syndrome. Common symptoms of an overactive bladder are:
sudden need to go to the bathroom and empty your bladder - known as urgency
need to urinate more often than usual - known as increased urinary frequency
accidental urine leakage - known as urgency incontinence.
There are many factors that can cause these issues, ranging from drinking too much alcohol or caffeine, to bladder inflammation, or nerve injury. Other potential causes also include urinary tract infections or increased pressure on your tummy caused by pregnancy or being overweight.
Betmiga contains an active ingredient called mirabegron, which works by relaxing the muscles of the bladder. By doing this, it reduces the urgent need to use the bathroom and helps you regain control over your bladder.
Mirabegron, the active ingredient in Betmiga, works by activating specific receptors in the smooth muscle of the bladder, known as beta-3 receptors. As a result, the bladder muscles relax, allowing the bladder to hold more urine and contract less frequently. This means you'll have fewer instances of sudden urges to pee and fewer unplanned trips to the bathroom.
Betmiga also has a very clever way to deliver the active ingredient in your body, called slow release or prolonged release. This means that the tablets release the active ingredient slowly and steadily into your body over time. By doing so, the tablets maintain a steady level of the drug in your system, providing you with a more consistent and long-lasting effect. So, the great thing is, you don't need to take them as often as regular tablets.
Betmiga tablets are available in two different dosages: Betmiga 25mg and Betmiga 50mg. Usually, the recommended dose for adults is one 50mg tablet by mouth once a day. In some cases, for instance if you have kidney or liver problems, your clinician may reduce your dose to one 25mg tablet by mouth once daily.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Remember to always take your medicine exactly as your doctor advises. Here are a few general guidelines to follow:
While what time of day you take it is not important, it’s best to take Betmiga at the same time each day. This will help you to build a habit and remember to take the pill.
Mirabegron, the active ingredient in Betmiga, starts to work pretty quickly in your body. It only takes about 3 to 4 hours for it to reach peak levels in your bloodstream and start relaxing the muscle surrounding your bladder.
Don’t be alarmed if you don’t notice an immediate effect, you need to stick with it for the long haul. This is because it can take between 4 to 8 weeks for you to notice major improvements in your symptoms.
If you accidentally take more Betmiga tablets than prescribed or if someone else takes them unintentionally, you should seek immediate help from your doctor, pharmacist or hospital. An overdose of Betmiga may cause symptoms such as a strong or forceful heartbeat, a faster pulse or higher blood pressure levels.
If you forget to take your medication, take the missed dose as soon as you remember, unless you have less than 6 hours before your next scheduled dose. In this case, skip the missed pill and continue with your regular medication schedule. You should not take a double dose to make up for the forgotten one. If you miss several doses, inform your doctor and ask for guidance.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Causes - Urinary incontinence. [online] NHS. Available at:
Betmiga 50 mg prolonged-release tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at:
Mirabegron: medicine to treat the symptoms of overactive bladder. [online] nhs.uk. Available at:
Staskin, D., Herschorn, S., Choudhury, N., Stoelzel, M., Heesakkers, J. and Siddiqui, E. (2020). Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. European Urology, 77(1), pp.119–128.
Mitcheson, D., Klecka, J., Cummings, J., Drogendijk, T., Dorrepaal, C. and Martin, N. (2013). Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder. European Urology, 63(2), pp.296–305.
Angulo, J.C., Cambronero, J., Høye, K., Milsom, I., Radziszewski, P., Rechberger, T., Boerrigter, P., Drogendijk, T., Wooning, M. and Chapple, C. (2013). Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial. European Urology, 63(2), pp.283–295. doi
Weiner, Lauren S., Roberts-Toler, C., Elía, E., Kessler, Skyler H., Kahn, Peter A., English, J., Chatman, K., Trauger, Sunia A., Doria, A. and Kolodny, Gerald M. (2015). Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist. Cell Metabolism, [online] 21(1), pp.33–38. doi:
Mangel, J., Staskin, D., Herschorn, S., Elsouda, D. and Schermer, C.R. (2020). Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatrics, 20(1). doi:
Registered with GMC (No. 4624794)
Meet Daniel
Registered with GPhC (No. 2202465)
Meet Sanjeda
Registered with GPhC (No. 2070724)
Meet Craig
Registered with GPhC (No. 2070338)
Meet RuaraidhDelivery, consultation, treatment. It’s all included in the price.
| Quantity | Starting from |
|---|---|
| 30 tablet(s) | £72.95 |
| 60 tablet(s) | £129.95 Save £15.95 |
| 90 tablet(s) | £187.95 Save £30.90 |
| Quantity | Starting from |
|---|---|
| 30 tablet(s) | £72.95 |
| 60 tablet(s) | £129.95 Save £15.95 |
| 90 tablet(s) | £187.95 Save £30.90 |
| Quantity | Starting from |
|---|---|
| 28 Tablets | £41.95 |
| 56 Tablets | £68.95 Save £14.95 |
| 84 Tablets | £96.95 Save £28.90 |
| Quantity | Starting from |
|---|---|
| 28 Capsule | £67.95 |
| 56 Capsule | £119.95 Save £15.95 |
| 84 Capsule | £171.95 Save £31.90 |
| Quantity | Starting from |
|---|---|
| 28 Capsule | £74.95 |
| 56 Capsule | £132.95 Save £16.95 |
| 84 Capsule | £189.95 Save £34.90 |
| Quantity | Starting from |
|---|---|
| 30 Tablets | £47.95 |
| 60 Tablets | £81.95 Save £13.95 |
| 90 Tablets | £113.95 Save £29.90 |
| Quantity | Starting from |
|---|---|
| 30 Tablets | £73.95 |
| 60 Tablets | £130.95 Save £16.95 |
| 90 Tablets | £188.95 Save £32.90 |
| Quantity | Starting from |
|---|---|
| 30 Tablets | £24.95 |
| 60 Tablets | £35.95 Save £13.95 |
| 90 Tablets | £47.95 Save £26.90 |
| Quantity | Starting from |
|---|---|
| 30 Tablets | £24.95 |
| 60 Tablets | £35.95 Save £13.95 |
| 90 Tablets | £47.95 Save £26.90 |
| Quantity | Starting from |
|---|---|
| 30 Tablets | £63.95 |
| 60 Tablets | £113.95 Save £13.95 |
| 90 Tablets | £159.95 Save £31.90 |
| Quantity | Starting from |
|---|---|
| 30 Tablets | £84.95 |
| 60 Tablets | £153.95 Save £15.95 |
| 90 Tablets | £222.95 Save £31.90 |
We know health, but you know you.
Our experts tell you what’s safe, but you decide what’s best.
Answer a few questions and tell us about yourself. Get tailored advice from our clinicians so you can choose better.
Choose your treatment and how often you have it delivered.
We know things change. It’s the nature of life. We’ll check in regularly to make sure your treatment is still right for you.
Pause. Change. Skip. Start again. Any time you like.
Fast, slick service. Very easy to amend subscription when required.
Arrived second day coz they used royal mail instead of DPD.
All nice
All good.
Great service
Express service
Our average rating based on 16185 reviews.
Urinary incontinence: Here are some other options.
Branded treatment that can help your symptoms in four weeks. Available in three different strengths.
Branded, delayed-release oxybutynin. Only one tablet per day, for full protection.
Generic version of Vesicare. Tablets to treat an overactive bladder.
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
If there’s a particular treatment or condition you’re looking for, tell us and we’ll look into it for you.
If you made a mistake on the gender selection, you can amend this by pressing 'Cancel' below and changing your gender. If you entered the correct gender but made a mistake on the treatment category selection, you can choose a different category by pressing 'Choose other treatment' below.
You have recently requested a change to your treatment plan which is under review.
We'll let you know once our clinician has reviewed your request.
Our prescriber has already made treatment suggestions for you
You can view and select an option from your account.
You already have treatment for under review.
You have a consultation being reviewed. Our prescriber will contact you soon.
You already have a treatment plan for on pause. You can restart or make changes to this from your account.
Submit your question here, or tell us if you’ve found an issue on our site.
We’ll get back to you very soon. We aim to respond to all queries in one working day.
You’re signed up to our newsletter. Keep an eye on your inbox for our latest update.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.
